Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;45(6):560-564.
doi: 10.15537/smj.2024.45.6.20230962.

Correlation between immunohistochemical staining and clinicopathological findings in endometrial carcinoma

Samah N Saharti  1 , Fadwa J Altaf  1
Affiliations

Correlation between immunohistochemical staining and clinicopathological findings in endometrial carcinoma

Samah N Saharti et al. Saudi Med J. 2024 Jun.

Abstract

Objectives: To analyze the immunohistochemical staining pattern of mismatch repair (MMR) proteins and p53 in endometrial carcinoma cases, including different subtypes and stages, to gain insights into their role in the pathogenesis and clinical behaviour of this malignancy.

Methods: In this study, we investigate the association between MMR deficiency, p53 mutational status, and clinical outcomes in various subtypes of endometrial carcinoma. The immunohistochemical staining pattern of MMR proteins in 96 cases of endometrial carcinoma have been analyzed, including 72 endometrioid, 14 papillary serous, 5 clear cell, and 5 mixed Müllerian tumor.

Results: The results showed that 36 cases were MMR deficient, with the majority being of endometrioid subtype. The p53 immunostain showed a mutational pattern in a subset of cases, with a documented dismal prognosis. However, aforementioned stains failed to predict synchronous or metachronous cancers in 5 patients.

Conclusion: These findings highlight the importance of MMR and p53 immunohistochemical staining in the classification, and prognosis of endometrial carcinoma.

Keywords: clinical outcomes; endometrial carcinoma; immunohistochemistry; mismatch repair proteins; p53 mutation.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. American Cancer Society. Cancer Facts and Figures. [Updated 2021; accessed 2024 May 15]. Available from: https://www.cancer.org/cancer/types/endometrial-cancer/about/key-statist...
    1. Saudi Health Council. Cancer incidence report: Saudi Arabia. [Updated 2020; 2023 Nov 15]. Available from: https://shc.gov.sa/Arabic/NCC/Activities/AnnualReports/Cancer%20Incidenc...
    1. Moch H. Female genital tumours: WHO classification of tumours, volume 4. [Updated 2020; accessed 2023 Nov 15]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-O...
    1. Bell DW, Ellenson LH. Molecular genetics of endometrial carcinoma. Annu Rev Pathol 2019; 14: 339–367. - PubMed
    1. Tabata J, Takenaka M, Okamoto A. Molecular typing guiding treatment and prognosis of endometrial cancer. Gynecology and Obstetrics Clinical Medicine 2023; 3: 7–17.

Substances